Taysha Gene Therapies Inc (NAS:TSHA)
$ 3.43 0.3 (9.58%) Market Cap: 641.47 Mil Enterprise Value: 578.20 Mil PE Ratio: 0 PB Ratio: 11.91 GF Score: 29/100

Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 02:00PM GMT
Release Date Price: $9.51 (-4.90%)
Unidentified Analyst

Good morning, and thank you for joining us today. My name is [Fauci Kash], and I'm an analyst at JPMorgan Selfcare Group. Before we get started, I just wanted to note that there will be no Q&A for the session. And with that, I'll pass it over to our speakers, RA Session, President, CEO and Founder of Taysha Gene Therapies; and Suyash Prasad, Medical Officer and Head of R&D.

R. A. Session
Taysha Gene Therapies, Inc. - Founder, President, CEO & Director

Thanks, [Fauci]. Good morning, everyone. Thank you, guys, for having us this morning. I'm happy to be presenting an initial overview of our story. I'll just start with some forward-looking statements here. And here's a summary of the company really why we're so excited about what lies ahead for 2022, just starting with a couple of near-term value inflection points. We'll be reporting long-term durability and long-term safety data on our high-dose cohorts and our other therapeutic doses, from our lead program, TSHA-120 giant axonal neuropathy later this month.

We'll also be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot